Numeta G 13 % E (Valine, Ornithine Hydrochloride, Alanine, Arginine, Cysteine, Histidine, Isoleucine, Leucine, Methio)

Numeta G 13% E is used in clinical nutrition to address protein and amino‑acid requirements in several metabolic conditions.

• Critical illness: helps provide the essential amino acids needed for tissue repair and immune function.
• Post‑operative recovery: supports protein synthesis for wound healing.
• Severe malnutrition: supplies a balanced amino‑acid profile to restore nitrogen balance.
• Chronic kidney disease: offers a controlled amino‑acid composition that is easier for the kidneys to process.
• Liver disease of cirrhosis or failure : provides a form of protein that is metabolised with reduced hepatic stress.

• Numeta G 13% E provides a mixture of essential and non‑essential amino acids that are directly absorbed in the gastrointestinal tract. The amino acids enter the bloodstream, where they serve as substrates for protein synthesis, support nitrogen balance, and act as precursors for neurotransmitters and metabolic intermediates, thereby aiding tissue repair and metabolic stability in patients with increased nutritional needs.

Numeta G 13% E may cause adverse reactions that are generally mild and related to its composition.

Common Side Effects

• Nausea: mild stomach upset reported by some patients.
• Diarrhea: loose stools occurring after oral administration.
• Abdominal discomfort: cramping or bloating sensations.
• Metallic taste: transient alteration in taste perception.
• Hypernatremia: slight increase in serum sodium in susceptible individuals.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, or swelling indicating hypersensitivity.
• Anaphylaxis: severe, potentially life‑threatening systemic reaction.
• Metabolic acidosis: rare disturbance in acid‑base balance.
• Hyperosmolarity: elevated serum osmolarity in patients with impaired renal function.
• Seizure risk: extremely rare neurological event linked to electrolyte shifts.

When using Numeta G 13% E, clinicians should consider several safety measures.

• Assess renal function: evaluate kidney performance before initiating therapy.
• Monitor electrolytes: regularly check serum sodium, potassium and osmolarity.
• Evaluate nutritional status: ensure the product matches the patient’s protein needs.
• Adjust for liver disease: modify dosage in hepatic impairment.
• Use caution in pregnancy: limited data, weigh benefits against potential risks.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Numeta G 13% E can interact with other medications and nutritional products.

Major Interactions (Avoid)

• High‑protein supplements: concurrent use may cause excess nitrogen load.
• Sodium‑containing IV fluids: combined sodium load can increase risk of hypernatremia.

Moderate Interactions (Monitor Closely)

• Diuretics: may amplify electrolyte disturbances.
• ACE‑ inhibitors: potential for altered potassium levels.
• Antiepileptic drugs: amino‑acid composition may affect drug metabolism.
• Oral anticoagulants: changes in plasma protein binding could modify effect.
• Proton‑pump inhibitors: may affect gastric pH and absorption of amino acids.